Amphotericin B has long been the mainstay in the treatment of systemic
fungal infections, but its nephrotoxicity limits the dosage that can
be used. New lipid-based forms may allow higher dosing with less nephr
otoxicity. Unfortunately, these new forms are substantially more expen
sive, and data from randomized clinical trials of their relative effic
acy are as yet limited.